Zoll said the lawsuit will not have a significant effect on its profits.

Alsius said it is reviewing the suit, and is confident in the strength of its intellectual property.

Zoll chief financial officer Ernest Whiton said the Food and Drug Administration has approved hypothermia induction as a way to reduce a patient’s body temperature. He added that doctors use the treatment on a variety of other ailments.

“It’s using hypothermia as a therapy to manage a patient’s temperature in therapy to treat other issues that a patient has, Whiton said.